Lupin rises on receiving EIR from USFDA for Aurangabad facility

22 Aug 2017 Evaluate

Lupin is currently trading at Rs. 939.60, up by 16.80 points or 1.82% from its previous closing of Rs. 922.80 on the BSE.

The scrip opened at Rs. 937.20 and has touched a high and low of Rs. 950.55 and Rs. 937.20 respectively. So far 20,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1590.00 on 09-Sep-2016 and a 52 week low of Rs. 920.00 on 21-Aug-2017.

Last one week high and low of the scrip stood at Rs. 975.00 and Rs. 920.00 respectively. The current market cap of the company is Rs. 42,599.00 crore.

The promoters holding in the company stood at 46.70%, while Institutions and Non-Institutions held 40.66% and 12.63% respectively.

Lupin has received notification that the inspection carried out by the US Food and Drug Administration (USFDA) in April 2017 at its Aurangabad facility is now closed and the agency has issued an Establishment Inspection Report (EIR). This closes all outstanding USFDA inspections at Lupin’s Aurangabad facility.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.


Lupin Share Price

2089.65 -0.50 (-0.02%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×